FY2025 EPS Forecast for Fulcrum Therapeutics Cut by Analyst

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Stock analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for shares of Fulcrum Therapeutics in a research note issued to investors on Thursday, October 30th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($1.19) for the year, down from their prior forecast of ($1.18). The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share. Cantor Fitzgerald also issued estimates for Fulcrum Therapeutics’ FY2026 earnings at ($1.11) EPS.

A number of other equities analysts also recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Wednesday, October 8th. Piper Sandler reissued an “overweight” rating and issued a $16.00 target price (up from $12.50) on shares of Fulcrum Therapeutics in a research report on Thursday. Leerink Partners set a $20.00 target price on Fulcrum Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. Wall Street Zen downgraded shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Fulcrum Therapeutics in a report on Monday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $13.00.

Fulcrum Therapeutics Trading Up 1.7%

Shares of FULC stock opened at $8.75 on Monday. The stock has a market capitalization of $473.55 million, a P/E ratio of -7.42 and a beta of 3.02. Fulcrum Therapeutics has a 12-month low of $2.32 and a 12-month high of $10.11. The firm’s 50 day moving average is $8.20 and its 200 day moving average is $7.07.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.02).

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Y Intercept Hong Kong Ltd purchased a new position in Fulcrum Therapeutics during the third quarter valued at approximately $104,000. Strs Ohio lifted its holdings in Fulcrum Therapeutics by 3.7% during the third quarter. Strs Ohio now owns 77,900 shares of the company’s stock valued at $717,000 after purchasing an additional 2,800 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Fulcrum Therapeutics during the third quarter valued at approximately $943,000. Simplify Asset Management Inc. lifted its holdings in Fulcrum Therapeutics by 13.8% during the third quarter. Simplify Asset Management Inc. now owns 83,234 shares of the company’s stock valued at $766,000 after purchasing an additional 10,080 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in shares of Fulcrum Therapeutics by 108.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after buying an additional 3,697 shares in the last quarter. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.